BBV154 - A novel adenovirus vectored, intranasal vaccine for COVID-19 | India Science, Technology & Innovation - ISTI Portal

×

Acces sibility Controls

BBV154 - A novel adenovirus vectored, intranasal vaccine for COVID-19

Implementing Organization

Bharat Biotech Pvt. Ltd., Hyderabad

About

DBT-BIRAC supported India's first Intranasal vaccine to prevent COVID-19 by Bharat Biotech private limited

Outcome / Output

Immune responses at the site of infection (in the nasal mucosa) – essential for blocking both infection and transmission of COVID-19. The technology helps for pandemic preparedness

Source

Source URL

technologies/bbv154-novel-adenovirus-vectored-intranasal-vaccine-covid-19

Related Research

Quick Information

Focus Area

Vaccines, Infectious Diseases

Status

completed

Disclaimer: Information available on this portal is sourced from various organizations and is provided for informational purposes only. Users are advised to verify details from the respective official sources.

Latest Updates

Loading…